Unprecedented Syndrome of Nervous System, Bipolar: Clinical Advancement in Cure using iPSCs Cells

Author(s):  
Prithiv Kumar K R

Severe illness such as bipolar is most common in developing countries and most populations are affected. Stem cell therapy has been a solution to this cognitive or social defect. This chapter is all about balancing and targeting modulation in the brain but also regenerating cells. With pathological damage in mental illness, there is novel interference such as modulation of a particular cell population. In the particular case of damage, oligodendrites played a crucial role. In this chapter, oligodendrites reveal calcium signals in neural cells. The stimulating mechanism of oligodendrites helps in the proliferation, maturation and myelination response of transplanted cells. The calcium signaling response regulates the neural progenitor cell proliferation, migration, differentiation synaptic plasticity which involves neuropsychiatric diseases in humans. Protein annotation and protein-protein interaction have been highlighted in this chapter. There are 119 calcium-activated proteins in the neuropsychiatry of the human brain. The calcium channel stimulating of stem cells zeros on the advantage of calcium stimulated stem cells and transplants the signal, to channel the drugs in a devised delivery system. This local delivery guidance of the brain delivery method is visualized using brain imaging techniques, providing a unique approach to treatment in psychiatry patients. It was found in our experiments that preconditioning stem cell therapy had high potential during transplantation and advised cared stimulations in procaine shell, synaptic modulation and myelin repair.

2021 ◽  
Vol 14 (4) ◽  
pp. 321
Author(s):  
Jung Hak Kim ◽  
So Young Kim ◽  
Bokyung Kim ◽  
Sang Rae Lee ◽  
Sang Hoon Cha ◽  
...  

Stroke is a serious, adverse neurological event and the third leading cause of death and disability worldwide. Most strokes are caused by a block in cerebral blood flow, resulting in neurological deficits through the death of brain tissue. Recombinant tissue plasminogen activator (rt-PA) is currently the only immediate treatment medication for stroke. The goal of rt-PA administration is to reduce the thrombus and/or embolism via thrombolysis; however, the administration of rt-PA must occur within a very short therapeutic timeframe (3 h to 6 h) after symptom onset. Components of the pathological mechanisms involved in ischemic stroke can be used as potential biomarkers in current treatment. However, none are currently under investigation in clinical trials; thus, further studies investigating biomarkers are needed. After ischemic stroke, microglial cells can be activated and release inflammatory cytokines. These cytokines lead to severe neurotoxicity via the overactivation of microglia in prolonged and lasting insults such as stroke. Thus, the balanced regulation of microglial activation may be necessary for therapy. Stem cell therapy is a promising clinical treatment strategy for ischemic stroke. Stem cells can increase the functional recovery of damaged tissue after post-ischemic stroke through various mechanisms including the secretion of neurotrophic factors, immunomodulation, the stimulation of endogenous neurogenesis, and neovascularization. To investigate the use of stem cell therapy for neurological diseases in preclinical studies, however, it is important to develop imaging technologies that are able to evaluate disease progression and to “chase” (i.e., track or monitor) transplanted stem cells in recipients. Imaging technology development is rapidly advancing, and more sensitive techniques, such as the invasive and non-invasive multimodal techniques, are under development. Here, we summarize the potential risk factors and biomarker treatment strategies, stem cell-based therapy and emerging multimodal imaging techniques in the context of stroke. This current review provides a conceptual framework for considering the therapeutic targets and directions for the treatment of brain dysfunctions, with a particular focus on ischemic stroke.


2013 ◽  
Vol 5 (1) ◽  
Author(s):  
Venki F. Tangkuman ◽  
Denny J. Ngantung ◽  
Arthur Mawuntu

Abstract: Stroke is the second order of deaths for the age group above 60 years and the fifth order for the age group 15-59 years. Although there are many kinds of therapies applied to stroke, none are satisfactory cures. An alternative therapy which is very promising, the neural stem cell therapy, is expected to be able to ameliorate stroke patients better, and therefore, can decrease the morbidity and mortality of stroke cases. There are several kinds of stem cells used in research, inter alia embryonal and adult stem cells. The purpose of this stem cell therapy in neurological disorders is to replace the damaged neural cells or to improve their biological function for enhancing brain function. New neuron cells can be produced from stem cell transplantation. Moreover, the mature brain has the ability, although very limited, to  produce new neuron cells as a response to brain damage due to stroke. Keywords: neural stem cells, stroke, transplantation.     Abstrak: Stroke merupakan penyebab kematian urutan kedua pada kelompok usia di atas 60 tahun dan urutan kelima pada kelompok usia 15-59 tahun. Sampai sekarang ini stroke belum dapat disembuhkan dengan baik walaupun telah banyak jenis pengobatan yang digunakan. Salah satu pengobatan alternatif yang mungkin kelak akan mampu memulihkan pasien stroke secara memuaskan serta menurunkan angka morbiditas dan mortalitas kasus stroke di seluruh dunia khususnya Indonesia yaitu terapi sel punca neuronal. Transplantasi sel punca pada gangguan neurologik termasuk stroke yaitu untuk menggantikan atau memperbaiki fungsi biologik dari sel neuron yang rusak agar dapat mempertahankan atau memulihkan fungsi otak. Sel neuron baru dapat dihasilkan dari transplantasi sel punca. Selain itu, otak dewasa akan terpicu untuk membuat sel neuron baru sebagai respon terhadap kerusakan sehingga akan meningkatkan kualitas penyembuhan pasien stroke. Kata kunci: sel punca neuronal, stroke, transplantasi.


2012 ◽  
Vol 32 (7) ◽  
pp. 1317-1331 ◽  
Author(s):  
Koji Abe ◽  
Toru Yamashita ◽  
Shunya Takizawa ◽  
Satoshi Kuroda ◽  
Hiroyuki Kinouchi ◽  
...  

Recent stem cell technology provides a strong therapeutic potential not only for acute ischemic stroke but also for chronic progressive neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis with neuroregenerative neural cell replenishment and replacement. In addition to resident neural stem cell activation in the brain by neurotrophic factors, bone marrow stem cells (BMSCs) can be mobilized by granulocyte-colony stimulating factor for homing into the brain for both neurorepair and neuroregeneration in acute stroke and neurodegenerative diseases in both basic science and clinical settings. Exogenous stem cell transplantation is also emerging into a clinical scene from bench side experiments. Early clinical trials of intravenous transplantation of autologous BMSCs are showing safe and effective results in stroke patients. Further basic sciences of stem cell therapy on a neurovascular unit and neuroregeneration, and further clinical advancements on scaffold technology for supporting stem cells and stem cell tracking technology such as magnetic resonance imaging, single photon emission tomography or optical imaging with near-infrared could allow stem cell therapy to be applied in daily clinical applications in the near future.


Author(s):  
Preeti Dali ◽  
Pravin Shende

: Stem cell therapy efficiently targets the brain for most of the neurological disorders like migraine, Parkinsonism, schizophrenia, Alzheimer’s disease, and brain injury. The major obstacles in potential brain targeting are the physiological barriers like blood-brain-barrier and blood-cerebrospinal fluid barrier. The conventional injectable route or direct transplantation of stem cells results in brain injury and is less feasible clinically. The alternative to these invasive routes is the intranasal route that is non-invasive, easily repeatable technique, and highly effective in brain targeting without crossing the blood-brain barrier. Extensive research has been undertaken for the delivery of stem cells to the brain via the intranasal route that hold great potential in overcoming the existing barriers. Nanotechnology is emerging as a novel interdisciplinary filed in the arena of stem cell research. The combination of nanotechnology coupled with stem cell therapy has led to synergistic outcomes in diagnostic and therapeutic applications of neurological diseases.This review provides insights into stem cell-based nanotherapy for brain targeting via the intranasal route.


2005 ◽  
Vol 19 (3) ◽  
pp. 1-4 ◽  
Author(s):  
Yvette D. Marquez ◽  
Michael Y. Wang ◽  
Charles Y. Liu

Over the course of the past few decades, it has become apparent that in contrast to previously held beliefs, the adult central nervous system (CNS) may have the capability of regeneration and repair. This greatly expands the possibilities for the future treatment of CNS disorders, with the potential strategies of treatment targeting the entire scope of neurological diseases. Indeed, there is now ample evidence that stem cells exist in the CNS throughout life, and the progeny of these stem cells may have the ability to assume the functional role of neural cells that have been lost. The existence of stem cells is no longer in dispute. In addition, once transplanted, stem cells have been shown to survive, migrate, and differentiate. Nevertheless, the clinical utility of stem cell therapy for neurorestoration remains elusive. Without question, the control of the behavior of stem cells for therapeutic advantage poses considerable challenges. In this paper, the authors discuss the cellular signaling processes that influence the behavior of stem cells. These signaling processes take place in the microenvironment of the stem cell known as the niche. Also considered are the implications attending the replication and manipulation of elements of the stem cell niche to restore function in the CNS by using stem cell therapy.


2009 ◽  
Vol 35 (2) ◽  
pp. 85-93 ◽  
Author(s):  
L. Vija ◽  
D. Farge ◽  
J.-F. Gautier ◽  
P. Vexiau ◽  
C. Dumitrache ◽  
...  

2014 ◽  
Vol 20 ◽  
pp. S128-S131 ◽  
Author(s):  
Hideki Mochizuki ◽  
Chi-Jing Choong ◽  
Toru Yasuda

2020 ◽  
Vol 22 (3) ◽  
pp. 286-305 ◽  
Author(s):  
Shuai Zhang ◽  
Brittany Bolduc Lachance ◽  
Bilal Moiz ◽  
Xiaofeng Jia

Stem cells have been used for regenerative and therapeutic purposes in a variety of diseases. In ischemic brain injury, preclinical studies have been promising, but have failed to translate results to clinical trials. We aimed to explore the application of stem cells after ischemic brain injury by focusing on topics such as delivery routes, regeneration efficacy, adverse effects, and in vivo potential optimization. PUBMED and Web of Science were searched for the latest studies examining stem cell therapy applications in ischemic brain injury, particularly after stroke or cardiac arrest, with a focus on studies addressing delivery optimization, stem cell type comparison, or translational aspects. Other studies providing further understanding or potential contributions to ischemic brain injury treatment were also included. Multiple stem cell types have been investigated in ischemic brain injury treatment, with a strong literature base in the treatment of stroke. Studies have suggested that stem cell administration after ischemic brain injury exerts paracrine effects via growth factor release, blood-brain barrier integrity protection, and allows for exosome release for ischemic injury mitigation. To date, limited studies have investigated these therapeutic mechanisms in the setting of cardiac arrest or therapeutic hypothermia. Several delivery modalities are available, each with limitations regarding invasiveness and safety outcomes. Intranasal delivery presents a potentially improved mechanism, and hypoxic conditioning offers a potential stem cell therapy optimization strategy for ischemic brain injury. The use of stem cells to treat ischemic brain injury in clinical trials is in its early phase; however, increasing preclinical evidence suggests that stem cells can contribute to the down-regulation of inflammatory phenotypes and regeneration following injury. The safety and the tolerability profile of stem cells have been confirmed, and their potent therapeutic effects make them powerful therapeutic agents for ischemic brain injury patients.


2011 ◽  
Vol 10 (2) ◽  
pp. 122-128 ◽  
Author(s):  
N. S. Zhukova ◽  
I. I. Staroverov

Heart failure (HF) is one of the leading death causes in patients with myocardial infarction (MI). The modern methods of reperfusion MI therapy, such as thrombolysis, surgery and balloon revascularization, even when performed early, could fail to prevent the development of large myocardial damage zones, followed by HF. Therefore, the researches have been searching for the methods which improve functional status of damaged myocardium. This review is focused on stem cell therapy, a method aimed at cardiac function restoration. The results of experimental and clinical studies on stem cell therapy in coronary heart disease are presented. Various types of stem cells, used for cellular cardiomyoplasty, are characterised. The methods of cell transplantation into myocardium and potential adverse effects of stem cell therapy are discussed.


2011 ◽  
Vol 300 (5) ◽  
pp. G684-G696 ◽  
Author(s):  
R. C. Mifflin ◽  
I. V. Pinchuk ◽  
J. I. Saada ◽  
D. W. Powell

The subepithelial intestinal myofibroblast is an important cell orchestrating many diverse functions in the intestine and is involved in growth and repair, tumorigenesis, inflammation, and fibrosis. The myofibroblast is but one of several α-smooth muscle actin-positive (α-SMA+) mesenchymal cells present within the intestinal lamina propria, including vascular pericytes, bone marrow-derived stem cells (mesenchymal stem cells or hematopoietic stem cells), muscularis mucosae, and the lymphatic pericytes (colon) and organized smooth muscle (small intestine) associated with the lymphatic lacteals. These other mesenchymal cells perform many of the functions previously attributed to subepithelial myofibroblasts. This review discusses the definition of a myofibroblast and reconsiders whether the α-SMA+ subepithelial cells in the intestine are myofibroblasts or other types of mesenchymal cells, i.e., pericytes. Current information about specific, or not so specific, molecular markers of lamina propria mesenchymal cells is reviewed, as well as the origins of intestinal myofibroblasts and pericytes in the intestinal lamina propria and their replenishment after injury. Current concepts and research on stem cell therapy for intestinal inflammation are summarized. Information about the stem cell origin of intestinal stromal cells may inform future stem cell therapies to treat human inflammatory bowel disease (IBD).


Sign in / Sign up

Export Citation Format

Share Document